BioSpace News Archive

Marken, the clinical supply chain subsidiary of UPS Healthcare, announced they are adding a GMP-compliant depot in Los Angeles, California and a new GMP-compliant depot in Kiev, Ukraine.

In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC and other types of stem cells with streamlined cleanroom practices for growing clinical grade cell products.

Vitro Diagnostics, Inc., dba Vitro Biopharma, jointly with GIOSTAR - a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science - announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

Venus Medtech Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced a collaboration to bring Pi-Cardia’s Leaflex™ technology to China.

Teleflex Survey Finds That Men Taking Medication to Treat Benign Prostatic Hyperplasia May Have Concerns About Side Effects and The Number of Medications Prescribed

ChromaDex R&D program continues to pioneer NAD+ and Niagen® research and inks over 200 external research collaborations

EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that based on feedback from a meeting with the U.S.

Calithera Biosciences announced the appointment of Scott Garland to its board of directors.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune disease, announced that the first patient has been dosed in a Phase 1 study of NX-13, the Company’s novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease.

Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter